Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer
Mian Xi(Sun Yat-sen University), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Li Zhang(Sun Yat-sen University), Robert Shen(Mayo Clinic), Mengzhong Liu(Sun Yat-sen University), Christopher L. Hallemeier(Mayo Clinic in Arizona), Dipen M. Maru(The University of Texas MD Anderson Cancer Center), Michael G. Haddock(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Yadi Yang(Sun Yat-sen University), Linus Ho(The University of Texas MD Anderson Cancer Center), Carol C. Wu(The University of Texas MD Anderson Cancer Center), Wayne L. Hofstetter(The University of Texas MD Anderson Cancer Center), Hong Yang(Sun Yat-sen University)
Cited by 95
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
|Journal of Clinical Oncology|2018|976
Neuropeptide S
|Neuron|2004|516